Keyprime
1 known investors
Korean contract research organization providing non-human primate-based preclinical toxicology, PK and safety pharmacology studies.
Also known as ใํคํ๋ผ์๋ฆฌ์์น ยท Keyprime Research ยท ํคํ๋ผ์๋ฆฌ์์น
Investors ยท 1
Company profile
researched Aug 2026Keyprime Research (ใํคํ๋ผ์๋ฆฌ์์น) is a South Korean contract research organization (CRO) specializing in nonclinical, or preclinical, studies conducted in non-human primate (NHP) models. The company describes itself as a primate-focused testing organization whose service portfolio covers general toxicology (early screening studies, dose range finding studies and GLP repeat-dose toxicity studies required for drug approval), pharmacokinetics (measurement of blood concentration over time to determine half-life, peak concentration and duration of effect, and to set dosing levels and intervals), and safety pharmacology (evaluation of cardiovascular, central nervous and respiratory system effects). Additional offerings include evaluation and analysis services spanning clinical pathology and histopathology, SEND data services, and the sale of NHP-derived biological samples for bioanalytical method development and research use.
The company states it has established a range of administration routes, including oral, intravenous, subcutaneous and intramuscular dosing as well as ocular, intraneural and intrathecal administration, and that it continues to develop additional routes. It reports analytical experience with newer modalities such as antibody-drug conjugates (ADC), antisense oligonucleotides (ASO) and mRNA. Operations are run under approval of an Institutional Animal Care and Use Committee (IACUC), and the company reports GLP certification from Korea's Ministry of Food and Drug Safety for repeat-dose toxicity testing in primates.
A third-party company directory describes Keyprime Research as headquartered in Cheongju, South Korea, founded in 2021, privately held with 51-200 employees, and as part of the Biotoxtech (BTT) Group; the same directory positions it as a niche player relative to large global preclinical CROs.
Business model
Fee-for-service contract research: pharmaceutical and biotechnology sponsors contract Keyprime Research to run nonclinical toxicology, pharmacokinetic, safety pharmacology and analytical studies at its test facility, with a defined contract and study process. The company also sells NHP-derived biological samples for research and bioanalytical method development.
Revenue is generated from sponsor-funded study contracts for preclinical services and from sales of NHP-derived biological materials.
Traction
The company reports GLP certification for primate repeat-dose toxicity studies from the Ministry of Food and Drug Safety, IACUC approval for its animal research, and accumulated analytical experience across multiple new drug modalities. An external directory lists employment of 51-200 people.
Latest developments
The corporate website carries a 2025 copyright and an updated privacy policy effective 1 July 2024, and continues to advertise active service lines, open recruitment and its Osong Campus test facility.
โธFull profile โ market position, technology, go-to-market, geography
Market position
Positions itself as Korea's largest NHP-focused preclinical research partner and a CRO specializing in primate-model studies; an external directory classifies it as a niche player relative to global preclinical CROs such as Charles River Laboratories, Labcorp, WuXi AppTec and Envigo, and identifies it as part of the Biotoxtech Group.
Specialization in non-human primate models rather than general preclinical testing, standardized protocols applied from specimen acquisition through housing and procedures, GLP certification from the Ministry of Food and Drug Safety for primate repeat-dose toxicology, IACUC oversight and adherence to the 3Rs framework, an established range of specialized administration routes, and a secured NHP supply arrangement.
Technology
The company operates NHP housing and testing facilities with environmental control systems and specialized housing units, continuous monitoring of animal physiological parameters and environmental conditions, and pathogen exclusion protocols intended to keep macaque colonies microbiologically defined. Study data are managed with the Provantis preclinical data management system, and computerized systems are operated in compliance with 21 CFR Part 11 and ALCOA++ data integrity principles. Capabilities include clinical pathology, histopathology, bioanalysis of new modalities, multiple administration routes including ocular, intraneural and intrathecal, and SEND-format data delivery.
Go-to-market
Direct sales to sponsors through a published contract and study process, study inquiry and NHP material order forms, dedicated sales contact lines, downloadable company brief, and press release/notice sections; the company also maintains a LinkedIn presence.
Pharmaceutical and biotechnology companies conducting drug development programs that require nonclinical safety, toxicology and pharmacokinetic data in non-human primates, including developers of newer modalities such as ADCs, ASOs and mRNA therapeutics.
Geography
Headquartered and operating in South Korea, with its Osong Campus test facility at 193 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do. NHP procurement is supported through a strategic partnership with a supplier in Vietnam. The website is published in Korean and English.
Compiled by commissioned research from 6 cited public sources โ announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed โ not independently audited.
โธResearch sources ยท 6
primary sources listed
- Keyprimekeyprime.com ยท web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Keyprime do?
- Korean contract research organization providing non-human primate-based preclinical toxicology, PK and safety pharmacology studies.
- Who are Keyprime's investors?
- Keyprime's investors include Kiwoom Investment.